Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Roche Beats Rivals To Japan Tumor-Agnostic Market With World-First Rozlytrek Nod

Tue, 06/18/2019 - 9:33pm

Roche’s tumor-agnostic drug receives first approval globally in Japan following an expedited review, giving the Swiss group a lead over...

      Related Stories 

Q&A: SVP Elliott Levy On Amgen R&D's 'Singular Focus On Innovation'

Tue, 06/18/2019 - 1:10pm

Scrip spoke with Levy, senior vice president of global development, about the company's novel candidates for cardiovascular and inflammatory diseases...

      Related Stories 

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

Tue, 06/18/2019 - 12:52pm

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also...

      Related Stories 

CHART/TABLE: Pipeline Watch: A Phase III Start In Celiac Disease

Tue, 06/18/2019 - 7:40am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Novartis India's New Chief Has A Full Plate

Mon, 06/17/2019 - 3:17pm

Ex-AstraZeneca executive Sanjay Murdeshwar will lead Novartis in India. The incoming head faces multiple challenges including balancing profitable growth and...

      Related Stories 

Interview: Galapagos Pipeline In Good Shape

Mon, 06/17/2019 - 9:33am

Following more promising rheumatoid arthritis data on filgotinib at EULAR, the Belgian biotech's chief medical officer Walid Abi-Saab tells Scrip...

      Related Stories 

AbbVie Ups The Ante For Upadacitinib At EULAR

Mon, 06/17/2019 - 2:45am

With data showing the superiority of its JAK inhibitor over Humira, the US firm is looking beyond treating the symptoms...

      Related Stories 

Trade War Expansion? STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

Sun, 06/16/2019 - 6:40pm

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ChipScreen and marking a new rival...

      Related Stories 

Trade War Expands? New STAR Board Aims To Keep Lucrative China Biotech IPOs At Home

Sun, 06/16/2019 - 6:40pm

China has officially unveiled its newest stock market for pre-revenue high-tech companies, already attracting ShenZhen ChipScreen and marking a new...

      Related Stories 

Upsher-Smith Snaps Up Migraine Assets As Dr Reddy’s Hones Focus

Sun, 06/16/2019 - 5:07pm

Upsher-Smith has acquired US and other territory rights to two specialty product assets of Dr Reddy’s, which appears to be...

      Related Stories 

Enanta Hopes To Succeed In RSV With N-Protein Inhibition Approach

Fri, 06/14/2019 - 1:45pm

Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be...

      Related Stories 

Pages